EGFR and non-small cell lung carcinoma: Currently, two clinical trials based on combination of Fus1-gene based drug REQORSA and EGFR inhibitors erlotinib (https://clinicaltrials.gov/ct2/show/NCT01455389) and osimertinib (Acclaim-1, https://clinicaltrials.gov/ct2/show/NCT04486833) are underway for treatment of NSCLC patients.